{"id":"activated-cik","safety":{"commonSideEffects":[{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Cytokine release syndrome"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"CIK cells are a heterogeneous population of lymphocytes generated by culturing peripheral blood mononuclear cells with interferon-gamma and anti-CD3 antibodies, resulting in cells with both NK and T-cell characteristics. These cells recognize and eliminate tumor cells through perforin/granzyme-mediated cytotoxicity and death receptor pathways. The activated CIK product from Benhealth represents an adoptive cell therapy approach to cancer treatment.","oneSentence":"Activated CIK (cytokine-induced killer cells) are ex vivo expanded immune cells that target and kill cancer cells through multiple mechanisms including natural killer and T-cell pathways.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T02:20:42.615Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cancer (specific indications in phase 2 development not publicly detailed)"}]},"trialDetails":[{"nctId":"NCT07204496","phase":"","title":"A Clinical Study on the Safety, Tolerance, and Preliminary Efficacy of γδ-T Cell Injection in the Treatment of Advanced Bladder Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai 10th People's Hospital","startDate":"2025-09-26","conditions":"Advanced Bladder Cancer","enrollment":20},{"nctId":"NCT00699816","phase":"PHASE3","title":"Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma Patients","status":"COMPLETED","sponsor":"GC Cell Corporation","startDate":"2008-07","conditions":"Hepatocellular Carcinoma","enrollment":230},{"nctId":"NCT03983967","phase":"PHASE1, PHASE2","title":"Evaluate the Efficacy and Safety of 'Immuncell-LC' in Patients Undergoing Liver Transplantation","status":"COMPLETED","sponsor":"GC Cell Corporation","startDate":"2019-01-24","conditions":"Liver Transplantation","enrollment":19},{"nctId":"NCT02856815","phase":"PHASE2","title":"Safety and Efficacy of \"Immuncell-LC\" in TACE Therapy","status":"COMPLETED","sponsor":"GC Cell Corporation","startDate":"2018-05-28","conditions":"Carcinoma, Hepatocellular","enrollment":76},{"nctId":"NCT04214717","phase":"NA","title":"Study of DC-CIK Combined With Chemotherapy for Advanced Solid Tumor","status":"UNKNOWN","sponsor":"Yantai Yuhuangding Hospital","startDate":"2019-12-31","conditions":"Solid Tumor","enrollment":60},{"nctId":"NCT02752243","phase":"PHASE1, PHASE2","title":"CIK-Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After SCT.","status":"UNKNOWN","sponsor":"Peter Bader","startDate":"2016-03","conditions":"Myelodysplastic Syndromes, Acute Leukemia","enrollment":32},{"nctId":"NCT03329664","phase":"PHASE1, PHASE2","title":"Autologous Killer Cell Therapy in Colon Cancer Patients","status":"UNKNOWN","sponsor":"Sabz Biomedicals","startDate":"2020-02-09","conditions":"Colon Cancer Stage IV","enrollment":20},{"nctId":"NCT02851784","phase":"PHASE2, PHASE3","title":"Combination Therapy of Microwave Ablation and Cellular Immunotherapy for Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2009-12","conditions":"Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT03146637","phase":"PHASE2","title":"Study of Activated CIK Armed With Bispecific Antibody for Advanced Liver Cancer","status":"UNKNOWN","sponsor":"Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.","startDate":"2017-05-01","conditions":"Advanced Liver Cancer","enrollment":80},{"nctId":"NCT03524274","phase":"PHASE2","title":"Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Colorectal Cancer","status":"WITHDRAWN","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2018-04-05","conditions":"Advanced Colorectal Cancer","enrollment":""},{"nctId":"NCT03509298","phase":"PHASE2","title":"Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Pancreatic Cancer","status":"WITHDRAWN","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2018-04-12","conditions":"Advanced Pancreatic Cancer","enrollment":""},{"nctId":"NCT03501056","phase":"PHASE2","title":"Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Lung Cancer","status":"WITHDRAWN","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2018-03-27","conditions":"Advanced Lung Cancer","enrollment":""},{"nctId":"NCT03540199","phase":"PHASE2","title":"Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Kidney Cancer","status":"WITHDRAWN","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2018-04-10","conditions":"Advanced Kidney Cancer","enrollment":""},{"nctId":"NCT03484962","phase":"PHASE2","title":"Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Liver Cancer","status":"WITHDRAWN","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2018-03-25","conditions":"Advanced Liver Cancer","enrollment":""},{"nctId":"NCT03524261","phase":"PHASE2","title":"Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Breast Cancer","status":"WITHDRAWN","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2019-05-20","conditions":"Advanced Breast Cancer","enrollment":""},{"nctId":"NCT03554395","phase":"PHASE2","title":"Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Gastric Cancer","status":"WITHDRAWN","sponsor":"Fuda Cancer Hospital, Guangzhou","startDate":"2018-04-05","conditions":"Advanced Gastric Cancer","enrollment":""},{"nctId":"NCT04476641","phase":"PHASE2","title":"A Study of DC-CIK Immunotherapy in the Treatment of Solid Tumors","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2016-05-06","conditions":"Liver Cancer, Kidney Cancer, Nasopharyngeal Cancer","enrollment":686},{"nctId":"NCT03944980","phase":"PHASE3","title":"Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Advanced Lung Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2019-06-01","conditions":"IIIB/IIIC/IV Lung Cancer","enrollment":146},{"nctId":"NCT03158480","phase":"NA","title":"Safety and Efficacy of Immune Therapy for Condyloma","status":"UNKNOWN","sponsor":"Shenzhen Second People's Hospital","startDate":"2017-06-25","conditions":"Condylomata Acuminata","enrollment":80},{"nctId":"NCT03057340","phase":"PHASE1","title":"The Treatment of Advanced Lung Cancer With Dribbles Antigen by Targeting Activation of Tcells","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2017-06-01","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT01235845","phase":"PHASE1, PHASE2","title":"Dendritic Cell (DC) Activated Cytokine-induced Killer Cell (DCIK) Combined With DC Treatment for Glioma","status":"UNKNOWN","sponsor":"Qingdao University","startDate":"2011-01","conditions":"Malignant Glioma","enrollment":30},{"nctId":"NCT01240005","phase":"PHASE1, PHASE2","title":"Cytokine Induced Killer Cells Stimulated by DC Immunotherapy for Renal Cell Carcinoma","status":"UNKNOWN","sponsor":"Qingdao University","startDate":"2011-01","conditions":"Renal Cell Carcinoma","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Activated CIK","genericName":"Activated CIK","companyName":"Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.","companyId":"benhealth-biopharmaceutical-shenzhen-co-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"Activated CIK (cytokine-induced killer cells) are ex vivo expanded immune cells that target and kill cancer cells through multiple mechanisms including natural killer and T-cell pathways. Used for Cancer (specific indications in phase 2 development not publicly detailed).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}